10-Q: Pressure BioSciences Reports Q1 2024 Results, Including Uncle Buds Acquisition

Pressure BioSciences, Inc. reports a decrease in revenue for Q1 2024 compared to Q1 2023, alongside the acquisition of Uncle Buds Health & Wellness.

Summary

• Pressure BioSciences, Inc. (PBIO) reported its Q1 2024 financial results, noting a 53% decrease in total revenue, amounting to $349,257, compared to $740,600 in Q1 2023.
• The decrease in revenue is attributed to lower cell disruptor instrument sales and reduced PBI Agrochem material sales.
• The company's gross profit margin decreased to 20% in Q1 2024 from 52% in Q1 2023, due to fewer instrument sales and no sales of high-margin PBI Agrochem materials.
• Research and development expenses decreased to $272,023 from $435,646, primarily due to lower stock-based compensation expenses.
• Selling and marketing expenses also decreased to $130,173 from $226,015, again due to lower stock-based compensation and reduced salary expenses.
• General and administrative expenses decreased significantly to $1,198,309 from $3,358,056, mainly due to lower stock option expenses.
• The operating loss was $1,484,558 for Q1 2024, compared to $3,637,745 for Q1 2023.
• Interest expense increased to $5,384,991 from $3,893,686, due to increased convertible debt and merchant cash loans.
• The net loss attributable to common stockholders was $8,706,476 ($0.22 per share) for Q1 2024, compared to $7,289,641 ($0.46 per share) for Q1 2023.
• The company completed the acquisition of Uncle Buds Health & Wellness in January 2024, aiming to leverage its direct-to-consumer capabilities.
• As of March 31, 2024, the company's financial statements raise substantial doubt about its ability to continue as a going concern due to inadequate working capital resources.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to decreased revenue and gross profit margin, and concerns about the company's ability to continue as a going concern. However, the acquisition of Uncle Buds and efforts to reduce operating expenses provide some positive aspects.

Positives

• Operating loss decreased by $2,153,187, or 59%, due to significant expense reductions in R&D, selling & marketing, and G&A.
• The company successfully acquired Uncle Buds Health & Wellness, expanding its market presence into the direct-to-consumer sector.
• Research and development expenses decreased to $272,023 for Q1 2024 compared to $435,646 for Q1 2023.
• Selling and marketing expenses were $130,173 for Q1 2024 compared to $226,015 for Q1 2023.
• General and administrative expenses were $1,198,309 for Q1 2024 compared to $3,358,056 for Q1 2023.

Negatives

• Total revenue decreased by 53% to $349,257 in Q1 2024 compared to $740,600 in Q1 2023.
• Gross profit margin decreased to 20% in Q1 2024 from 52% in Q1 2023.
• Interest expense increased to $5,384,991 for Q1 2024 compared to $3,893,686 for Q1 2023.
• The company's financial statements raise substantial doubt about its ability to continue as a going concern due to inadequate working capital resources.
• Net loss attributable to common stockholders was $8,706,476 ($0.22 per share) for Q1 2024 compared to $7,289,641 ($0.46 per share) for Q1 2023.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to inadequate working capital resources.
• The company's reliance on raising additional debt and equity capital poses a risk if financing is not available on acceptable terms.
• The company's need to take additional cost reduction measures, cease operations, or sell operating assets if sufficient financing is not obtained presents a significant risk.
• Any interruption to the continuous uptime and availability of the Uncle Buds website would result in likely loss of sales revenues.
• Any interruption to the availability and application of planned marketing expenditures supporting products offered through Uncle Buds would result in likely loss of sales revenues.

Future Outlook

The company anticipates synergies from combining existing commercial customers with the retail focus and customer list of Uncle Buds, as the company desires to use its existing products into the retail channel. The company has efforts in place to continue to raise cash through debt and equity offerings.

Industry Context

The acquisition of Uncle Buds reflects a trend of companies diversifying into the direct-to-consumer market, particularly in the health and wellness sector. The focus on UST platform aligns with the growing interest in nanoemulsion formulations for enhanced bioavailability of supplements and therapeutics.

Comparison to Industry Standards

• Given the limited information, a detailed comparison to industry standards is challenging.
• However, the decrease in revenue and gross profit margin suggests that Pressure BioSciences is underperforming compared to some of its peers.
• Companies like NanoSphere Health Sciences and Quicksilver Scientific also focus on advanced delivery systems, and comparing their financial performance could provide additional context.
• The high interest expense relative to revenue indicates a reliance on debt financing, which is a concern compared to companies with stronger balance sheets.

Related Party Transactions

• During the three months ended March 31, 2024, we received short-term convertible loans of $ 105,875 with $ 8,823 OID from related parties and repaid $ 63,300 of related party loans.
• All related party notes are convertible at $ 2.50 / share.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings.
• Employees may be affected by cost reduction measures or potential changes in business strategy.
• Customers could benefit from the expanded product offerings and potential synergies from the Uncle Buds acquisition.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company plans to continue raising cash through debt and equity offerings.
• The company aims to leverage the acquisition of Uncle Buds to drive revenue growth.
• The company intends to improve the effectiveness of the accounting group by augmenting existing resources with additional consultants or employees.

Key Dates

Keywords

Pressure BioSciences, PBIO, Uncle Buds, Q1 2024, Financial Results, Acquisition, Revenue, Net Loss, Going Concern, Ultra Shear Technology, BaroFold Technology, Pressure Cycling Technology, Convertible Debt, Stock Issuances